Evotec SE Stock Analysis & AI Score
Evotec SE (EVO) has an ST Score of 35.9 (C-), driven by its Forecast (A-) and held back by its Profitability (F). Analysts rate it Buy with a $3.00 price target (+96.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Evotec SE (EVO) has an ST Score of 35.9 (C-), driven by its Forecast (A-) and held back by its Profitability (F). Analysts rate it Buy with a $3.00 price target (+96.1% upside).
- Strongest
- ForecastA-
- Weakest
- ProfitabilityF
All factor grades
- ForecastA-
- ValuationB
- Financial StrengthC-
- GrowthC-
- MomentumD-
- ProfitabilityF
- Piotroski4/9
Contact
EVO stock: frequently asked questions
What is EVO's ST Score?
Evotec SE (EVO) has an ST Score of 35.9 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EVO a buy, hold, or sell?
Analysts rate EVO a Buy, with a price target of $3.00 (+96.1% vs the current price). Our ST Score grades it C- (35.9/100). The ST Score is a data-driven signal, not a recommendation.
What are EVO's factor grades?
Valuation B, Profitability F, Financial Strength C-, Momentum D-, Growth C-, Forecast A-.
What is EVO's valuation grade?
Evotec SE (EVO) earns a valuation grade of B, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EVO's growth grade?
Evotec SE (EVO) earns a growth grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EVO's profitability grade?
Evotec SE (EVO) earns a profitability grade of F, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EVO's financial strength grade?
Evotec SE (EVO) earns a financial strength grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EVO?
The average analyst price target for Evotec SE (EVO) is $3.00 from 7 analysts, which is +96.1% versus the recent price of $1.53.
What is EVO's Piotroski score?
Evotec SE (EVO) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.